OSE Immunotherapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from OSE Immunotherapeutics SA
Access all reports
OSE Immunotherapeutics SA is a French biotechnology company focused on developing immunotherapies for cancer, autoimmune diseases, and infectious diseases. The company’s pipeline includes innovative treatments aimed at modulating the immune system, including checkpoint inhibitors, therapeutic vaccines, and monoclonal antibodies. OSE Immunotherapeutics leverages proprietary technology platforms to design therapies that target specific immune pathways, with the goal of improving patient outcomes in conditions where immune response plays a critical role. The company collaborates with research institutions and pharmaceutical companies to advance its clinical programs. The company is headquartered in Nantes, France, and its shares are listed on Euronext Paris.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
OSE
Country
🇫🇷 France